Changes in Hematological Parameters with Pegylated Interferon in Chronic Hepatitis C Virus Infected Patients

  • Rehman, Aziz Ur (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Ali, Farhad (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Ali, Mashhood (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Alam, Ibrar (Department of Biotechnology, Bacha Khan University Charsadda) ;
  • Khan, Abdul Wali (Center of Biotechnology and Microbiology, University of Peshawar)
  • Published : 2016.05.01


The liver is one of the most common sites of cancer in the world, hepatocellular carcinoma (HCC) predominating. HCC is the sixth most common cancer and the third leading cause of cancer related death overall. Hepatitis C is a major risk factor and HCV is a rapid spreading virus which has become a problem globally, including in Pakistan. Interferon alpha therapy is used against HCV disease to regulate cell reproduction and to boost the immune system. In minute amounts interferon alpha is produced naturally by the immune system in HCV patients in response to hepatitis C virus and binds to receptors in the target cells and starts transcription of 20-30 genes due to which it develops an antiviral influence. Interferon is also administered artificially to overcome HCV disease and remove the biological effect of the virus from the infected site. The use of interferon or Peg-IFN plus Ribavirin treatment is also associated with adverse effects on body. For the current study, a convenient sample of 156 HCV positive patients of both males and females were taken. To collect blood CP and ALT, a reduction of level data and other important information were collected from the patients at regular intervals. Findings were 11.4 % in the red blood cells (RBC), 9.64 % in the total leukocyte count (WBC), 8.4 % in the hemoglobin levels (HB), 30.3 % in the platelet (Plt) count in both sexes. There was significant reduction in ALT levels due to Pegylated interferon plus ribavirin therapy. Hence strict haemotological monitoring of blood CP and ALT levels is necessary at regular intervals to reduce severe side effects which may lead to morbidity and mortality.


HCV;pegylated interferon;ALT;ribavirin;heamtological parameters


  1. Alam I, Ali I, Ali S, et al (2013). Impact of combination interferon therapy on the body weight, body fat and lean body mass of chronic hcv infected patients. J Antivir Anti retrovir, 6, 1-5.
  2. Alam I, Hassan S, Alam I, et al (2015). PAIgG and PAIgM levels in secondary dengue virus infections lead to thrombocytopenia in patients from KP, Pakistan. Asian Pac J Trop Biomed, 5, 801-5
  3. Alam I, Alam I, Ali I, et al (2014). Weight loss in HCV patients can be used as surrogate marker for evaluation of interferon (IFN-${\alpha}$) treatment efficacy a prospective pilot study. Pak J Pharm Sci, 27, 571-6.
  4. Aspinall R, Pockros P (2004). The management of side effects during therapy for hepatitis C. Alimentary Pharmacol Therapeutics, 20, 917-29.
  5. Cuerquis J, Alam I, Marino IR, et al (2014). Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation:effect of interferon-${\gamma}$ and tumor necrosis factor-${\alpha}$ stimulation. Cytotherapy, 16, 191-202.
  6. Elshahawi Y, Sany D (2015). Microalbuminuria and pegylated interferon in hepatitis-C patients.Saudi J Kidney Dis Transpl, 26, 1183-9.
  7. Fattovich G, Giustina G, Favarato S, et al (1996). A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol, 24, 38-47.
  8. Ghani MH, Masood N, Munir A, et al(2009). Haemotological disorders during interferon and ribavirin therapy in chronic hepatitis C patients. Med Channel, 15, 167-70.
  9. Hezode C, Fontaine H, Dorival C, et al (2013).Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme. J Hepatol, 59, 434-41.
  10. Hunyady B, Kovacs B (2011). Side-effects of interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection. Orv Hetil, 152, 1997-09.
  11. Ludovico A, Marta M, Piero L, et al (2011). The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon, 11, 240-6.
  12. Lagging M, Brown A, Mantry PS (2015). Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat, 23, 80-8.
  13. Iliecu G, Alam Z, White J, et al (2010). Haemotological monitoring of interferon based therapy for chronic viral hepatitis B and C. Hepatology. 14, 1102-11.
  14. Jacobson IM, Hutchison JG, Dusheiko G, et al (2011).Telaprevir for previouslyuntreated chronic hepatitis C virus infection. N Engl J Med, 364, 2405-16.
  15. Kumar, Y., Sharma, P., Bhatt, N et al (2015). Transarterial therapies for hepatocellular carcinoma: a comprehensive review with current updates and future directions. Asian Pac J Cancer Prev, 17, 473-8.
  16. Makkoch J, Praianantathavorn K, Sopipong W, et al (2015). Genetic variations in XRCC4 (rs1805377) and ATF6 (rs2070150) are not associated with hepatocellular carcinoma in Thai patients with hepatitis B virus infection. Asian Pac J Cancer Prev, 17, 591-5.
  17. Masood N, Hanif M, Munir A, et al (2010). End of treatment and biochemical response to interferon and ribavirin therapy in chronic hepatitis C patients. Med. Channel, 16, 219-222.
  18. Maasoumy B, Port K, Serrano B, et al(2013).The clinical significance of drug-druginteractions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther, 38, 1365-72.
  19. Ma J, Wang J-H (2014). 131 I-Labeled-metuximab plus transarterial chemoembolization in combination therapy for unresectable hepatocellular carcinoma: results from a multicenter phase iv clinical study. Asian Pac J Cancer Prev, 16, 7441-7.
  20. Nadeem A, Aslam M, Hussain T, et al (2007). Efficacy of combined interferon alpha and ribavirin therapy in patients of chronic hepatitis C. Pak J Physiol, 3, 32-40.
  21. National Institutes of Health (2002). Consensus Development Conference Statement: Management of Hepatitis C, June 10-12.
  22. Pawlotsky JM, Ali E, Jhon R, et al (1999). Diagnostic tests for hepatitis C. J Hepatol, 31, 71-9.
  23. Pouresmaeeli M, Davila M, et al (2015). Efficacy and tolerability of peginterferonalpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C. Hepat Mon, 15, e30780.
  24. Saeed K, Hussain T, Kamran M, et al (2006). Effect of antiviral therapy on haemotological parameters in patients with chronichepatitis. Pak Armed Forces Med J, 56, 228-31.
  25. Sugimoto K, Kim SR, Port K, et al (2015). Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir pluspeginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma. Oncology, 2, 42-46.
  26. Smolic M, Cho SH (2013). Management of side effects induced by antiviral therapy for chronic hepatitis infection. Acta Med Croatica, 67, 383-7.
  27. Trakroo S, Qureshi K (2015). Successful treatment of chronic hepatitis c infection with direct-acting antivirals in a heart transplant recipient: a case report. Transplant Proc, 47, 2295-7.